These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Anti-hypertensive efficacy and tolerability of sustained-release prazosin hydrochloride. A Brazilian multicenter study].
    Author: Spritzer N.
    Journal: Arq Bras Cardiol; 1990 Oct; 55(4):263-6. PubMed ID: 2078143.
    Abstract:
    PURPOSE: To evaluate the efficacy and tolerability of a single daily dose of sustained-release (SR) formulation of prazosin hydrochloride. PATIENTS AND METHODS: 1393 outpatients in a multicenter open comparative trial. 644 patients had mild hypertension and 749 patients had moderate hypertension. The mean age was 47.63 years, 745 (53.52%) were male, 1011 (72.84%) white and 279 (20.1%) black. The patients received prazosin hydrochloride SR during 4 weeks in an initial dose of 1 mg, adjusted to a maximum of 6 mg in order to decrease the diastolic blood pressure (DBP) to 90 mmHg or less. RESULTS: The mean daily dose was 2.08 mg. At the end of the study, 1274 (91.46%) patients had DBP less than or equal to 90 mmHg or less. 624 patients were in the mild hypertension group and 650 patients were in the moderate hypertension group. The number of patients under DBP control in the first three weeks was 426 (first week), 844 (second week) and 1147 (third week). The DBP decreased from the mean value of 104 +/- 5 mmHg to 88 +/- 8 mmHg (p less than 0.05). The mean heart rate ranged from 82 +/- 9 beats/min (pre-treatment) to 80 +/- 8 beats/min (fourth week). Adverse effects were identified in 377 (27.06%) patients, total of 444 episodes, the more frequent being dizziness. Only 8 (2.12%) patients had to reduce the doses of prazosin hydrochloride SR and 5 (1.32%) had to discontinue the treatment on account of the adverse effects of the drug. CONCLUSION: Prazosin hydrochloride SR in a single daily dose seems to be an advance in the treatment of patients with mild and moderate hypertension.
    [Abstract] [Full Text] [Related] [New Search]